This site is intended for health professionals only
Sunday 21 April 2019
Share |

Topic: type 2 diabetes

September 14, 2017
In people with type 2 diabetes, Xultophy® (insulin degludec/liraglutide) significantly reduced a number of risk factors associated with an increased risk of cardiovascular disease, compared to basal insulin

According to a new post-hoc analysis presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD 2017), people treated with Xultophy® had significantly lower systolic blood pressure, lower total cholesterol as well as lower low-density lipoprotein cholesterol (so-called 'bad cholesterol'), and significant weight changes in favour of Xultophy® compared to people treated with basal insulin (insulin glargine U100 or insulin degludec).

September 16, 2016
Results were presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes 2016

Novo Nordisk has announced that the progression of kidney damage was significantly lower with Victoza® treatment vs placebo, as measured by urinary albumin creatinine ratio, both added to standard of care in 9340 adults with type 2 diabetes at high cardiovascular (CV) risk.

 

Similar significant results were observed between Victoza® and placebo across subgroups (with no, mild or moderate renal impairment).

 

September 16, 2015
Findings from a head-to-head trial have demonstrated a significantly greater reduction in blood sugar for liraglutide compared to lixisenatide in adults with type 2 diabetes

Findings from a head-to-head trial comparing Victoza® (liraglutide) and lixisenatide, both in combination with metformin, have demonstrated a significantly greater reduction in blood sugar (measured by HbA1c) for liraglutide compared to lixisenatide in adults with type 2 diabetes. (1) The results from the LIRA-LIXI trial were announced at the 51st Annual Meeting of the European Association for the Study of Diabetes (EASD) in Stockholm, Sweden.

 

September 15, 2015
Patients with type 2 diabetes also reported higher satisfaction with Tresiba® U200 highlighting an overall preference versus insulin glargine U100

New data presented today at the 51st annual meeting of the European Association for the Study of Diabetes (EASD) show that patients with type 2 diabetes receiving the U200 formulation of Tresiba® (insulin degludec) experienced significantly lower rates of confirmed hypoglycaemia and significantly reduced mean fasting blood glucose compared to those receiving insulin glargine U100. (1) Tresiba® U200 is twice as concentrated as U100, allowing patients to inject up to 160 units in a single injection, rather than in two separate injections.

 

September 15, 2015
Advice from Philip Newland-Jones, the Royal Pharmaceutical Society's Leadership Award winner

With the dramatic rise in the number of people living with type 2 diabetes there is an urgent need for more pharmacists who specialise in diabetes, the Royal Pharmaceutical Society's Leadership Award winner has advised.

 

Philip Newland-Jones, an Advanced Specialist Pharmacist Practitioner at University Hospital Southampton NHS Foundation Trust, won the award on Sunday 13 September for his outstanding leadership across several clinical, education and research fields within the area of diabetes, both locally and nationally.

March 30, 2015
Empagliflozin when added to metformin HCl lowers blood glucose, body weight and blood pressure. Side effects identified with empagliflozin plus metformin HCl were in line with the known safety profile of the individual compounds empagliflozin and metformin.

Empagliflozin when added to metformin HCl lowers blood glucose, body weight and blood pressure. Side effects identified with empagliflozin plus metformin HCl were in line with the known safety profile of the individual compounds empagliflozin and metformin.

January 20, 2015
Moderate chronic kidney disease affects up to 40% of all people with type 2 diabetes in the UK, which is approximately one million people (1,2). Type 2 diabetes costs the NHS a total of £21.8 billion in 2010/2011, with the complications of chronic kidney disease accounting for an estimated £753.8 million. These figures are predicted to rise to £35.6 billion for type 2 diabetes and £1.3 billion for kidney disease in people with type 2 diabetes by 2035/36 (3). The licence extension for Victoza® (liraglutide) increases clinicians’ prescribing options to help patients with both conditions achieve glucose control.
  • Moderate chronic kidney disease affects up to 40% of all people with type 2 diabetes in the UK, which is approximately one million people (1,2).
  • Type 2 diabetes costs the NHS a total of £21.8 billion in 2010/2011, with the complications of chronic kidney disease accounting for an estimated £753.8 million. These figures are predicted to rise to £35.6 billion for type 2 diabetes and £1.3 billion for kidney disease in people with type 2 diabetes by 2035/36 (3).
September 24, 2014
The mechanism by which statins increase the risk of type 2 diabetes has been investigated in a large-scale analysis from an international team led by researchers from UCL and the University of Glasgow, using information from genetic studies and clinical trials. Published in The Lancet, the work received support from a number of funders including the Medical Research Council, British Heart Foundation, Rosetrees Trust and National Institute for Health Research University College London Hospitals Biomedical Research Centre.

The mechanism by which statins increase the risk of type 2 diabetes has been investigated in a large-scale analysis from an international team led by researchers from UCL and the University of Glasgow, using information from genetic studies and clinical trials. Published in The Lancet, the work received support from a number of funders including the Medical Research Council, British Heart Foundation, Rosetrees Trust and National Institute for Health Research University College London Hospitals Biomedical Research Centre.

September 19, 2014
MSD, known as Merck & Co., Inc. in the United States and Canada, announced the presentation of the first data from the Phase 3 clinical development program for omarigliptin, an investigational once weekly DPP-4 inhibitor for the treatment of type 2 diabetes.
September 16, 2014
Boehringer Ingelheim and Eli Lilly and Company presented results from a 52-week Phase III study that demonstrated sustained efficacy of the investigational empagliflozin/linagliptin combination tablet in adults with Type 2 Diabetes (T2D) already taking metformin and in those who were previously untreated.

Boehringer Ingelheim and Eli Lilly and Company presented results from a 52-week Phase III study that demonstrated sustained efficacy of the investigational empagliflozin/linagliptin combination tablet in adults with Type 2 Diabetes (T2D) already taking metformin and in those who were previously untreated.

Results from the study, presented during the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD), also confirmed the safety profile of the combination tablet.

September 12, 2014
Intarcia Therapeutics, Inc. announced its participation in the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD), taking place in Vienna September 15 -19.

Intarcia Therapeutics, Inc. announced its participation in the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD), taking place in Vienna September 15 -19.

September 4, 2014
The Lancet Diabetes & Endocrinology has published the phase 3a DUALTM I study investigating IDegLira (insulin degludec/liraglutide; Xultophy®) once-daily, single injection insulin degludec (Tresiba®) and liraglutide (Victoza®).

The Lancet Diabetes & Endocrinology has published the phase 3a DUALTM I study investigating IDegLira (insulin degludec/liraglutide; Xultophy®) once-daily, single injection insulin degludec (Tresiba®) and liraglutide (Victoza®).

August 11, 2014
Diabetes Care has published phase IIIa findings that demonstrate a significantly greater glucose-lowering effect with IDegLira compared with insulin degludec.

Diabetes Care has published phase IIIa findings that demonstrate a significantly greater glucose-lowering effect with IDegLira (insulin degludec/liraglutide; Xultophy®) compared with insulin degludec.
People on IDegLira also experienced a low rate of hypoglycaemia, comparable with insulin degludec, and achieved a reduction in body weight when compared with treatment with basal insulin alone.(1)

June 26, 2014
Janssen has welcomed the publication of Final Guidance from the National Institute for Health and Care Excellence for canagliflozin.

Janssen has welcomed the publication of Final Guidance from the National Institute for Health and Care Excellence (NICE) for canagliflozin.
Canagliflozin is a new treatment option indicated for reducing blood glucose levels in people for whom diet and lifestyle measures or treatment with other blood glucose-lowering medicines, do not provide adequate control.(1,2)
It also has the additional benefits of modest weight loss (2–4%) and blood pressure reduction (although is not licensed for use in weight loss or blood pressure reduction).(1)

November 13, 2008
Study into diabetes drug shows how it fails to significantly reduce plaque buildup in arteries

teaser

September 12, 2008
New diabetes drug proven to be more effective and convenient than current treatment used

teaser

September 10, 2008
Type 2 diabetes drug found to reduce the risk of amputations

teaser

May 27, 2008
One million UK diabetics risk heart disease through poor adherence, says charity

teaser

May 23, 2008
Intensive therapy delays the progression of type 2 diabetes

teaser

January 22, 2008
The European Commission has approved Januvia (sitagliptin) for two additional uses for patients with type 2 diabetes, the drug's manufacturer Merck has announced.

teaser

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine